Ekf Diagnostics : Director / PDMR Shareholding

EKF Diagnostics Holdings plc (AIM: EKF) announces that on 23 June 2016, the Company was notified that Harwood Capital LLP ('Harwood') acquired 2,000,000 ordinary shares of 1 pence each in the capital of the Company ('Ordinary Shares') as investment manager to North Atlantic Smaller Companies Investment Trust PLC ('NAIT'). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.

Following the above transaction, which was completed on 23 June 2016 at a price of 11.75 pence per share, NAIT's interest is now in 72,428,103 Ordinary Shares, representing 15.60% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ('Oryx', whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.

The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 112,428,103 Ordinary Shares, representing 24.22% of the Company's issued share capital.

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
Panmure Gordon (UK) Limited Robert Naylor Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or [e-mail] 00 44 7980 541 893 00 44 7584 391 303